AUTHOR=Huang Lei , Liu Mei-Qing , Wan Chang-Qing , Cheng Ning-Ning , Su Yan-Bin , Zheng Yan-Peng , Peng Xiang-Lei , Yu Jie-Mei , Fu Yuan-Hui , He Jin-Sheng 

TITLE=The protective immunity induced by intranasally inoculated serotype 63 chimpanzee adenovirus vector expressing human respiratory syncytial virus prefusion fusion glycoprotein in BALB/c mice

JOURNAL=Frontiers in Microbiology

VOLUME=Volume 13 - 2022

YEAR=2022

URL=https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2022.1041338

DOI=10.3389/fmicb.2022.1041338

ISSN=1664-302X

ABSTRACT=Human respiratory syncytial virus (RSV) is a ubiquitous pediatric pathogen causing serious lower respiratory tract disease worldwide. No licensed vaccine is currently available. The serotype 26 human adenovirus vector  encoding pre-fusion conformation stabilized RSV-F protein (Ad26.RSV.preF) has proceeded to phase III clinical trial. In this work, our goal is to construct the serotype 63 chimpanzee adenovirus vector expressing pre-fusion conformation stabilized RSV-F protein (rChAd63/mDS-Cav1) and investigate the immune efficacy and safety in vivo. After immunizing mice via intranasal route, the rChAd63/mDS-Cav1 induced enhanced neutralizing antibody and specific CD8+ T cell responses as well as good immune protection with the absence of enhanced RSV disease (ERD) in BALB/c mice. The results indicate that rChAd63-mDS-Cav1 is a promising mucosal vaccine candidate against RSV infection and may represent effective and safe vaccine vector.